We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

32 hedge funds and large institutions have $111M invested in Kalaris Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

353% more capital invested

Capital invested by funds: $24.6M → $111M (+$86.8M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

72.33% more ownership

Funds ownership: 1.87% → 74.19% (+72%)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

38% less funds holding

Funds holding: 52 → 32 (-20)

91% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 22

Holders
32
Holders Change
-20
Holders Change %
-38.46%
% of All Funds
0.43%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
2
Increased
12
Reduced
13
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
+$112M
2
TCM
Tang Capital Management
California
+$2.79M
3
EC
EcoR1 Capital
California
+$1.8M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$99.4K
5
Bank of America
Bank of America
North Carolina
+$43.5K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.13M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$279K
3
Two Sigma Investments
Two Sigma Investments
New York
-$112K
4
BCM
BML Capital Management
Indiana
-$77.4K
5
Northern Trust
Northern Trust
Illinois
-$67.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$2.37K -$587 -60 -17%
CCM
27
Coldstream Capital Management
Washington
$1.67K +$2.04K +208 New
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$1.02K -$30.7K -3,132 -96%
PA
29
Parallel Advisors
California
$393 -$10 -1 -2%
FFA
30
Farther Finance Advisors
California
$264 – – –
EWA
31
EverSource Wealth Advisors
Alabama
$241 – – –
Barclays
32
Barclays
United Kingdom
$8 +$10 +1 New
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
– -$279K -28,888 Closed
Two Sigma Investments
34
Two Sigma Investments
New York
– -$112K -11,591 Closed
BCM
35
BML Capital Management
Indiana
– -$77.4K -8,011 Closed
Northern Trust
36
Northern Trust
Illinois
– -$67.1K -6,943 Closed
Citadel Advisors
37
Citadel Advisors
Florida
– -$64.5K -6,674 Closed
Jane Street
38
Jane Street
New York
– -$51.7K -5,355 Closed
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
– -$29.5K -3,033 Closed
Raymond James Financial
40
Raymond James Financial
Florida
– -$25.4K -2,630 Closed
Tudor Investment Corp
41
Tudor Investment Corp
Connecticut
– -$20.8K -2,157 Closed
VF
42
Virtu Financial
New York
– -$20K -2,025 Closed
Lido Advisors
43
Lido Advisors
California
– -$16.5K -1,710 Closed
TSS
44
Two Sigma Securities
New York
– -$13.7K -1,416 Closed
HF
45
HRT Financial
New York
– -$13K -1,373 Closed
PAS
46
Point72 Asia (Singapore)
Singapore
– -$11.3K -1,169 Closed
EGM
47
Engineers Gate Manager
New York
– -$6.77K -701 Closed
PI
48
PFG Investments
New York
– -$6.72K -696 Closed
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
– -$6.11K -632 Closed
Goldman Sachs
50
Goldman Sachs
New York
– -$5K -518 Closed
1
2
3

KLRS Hedge Fund Activity: Q1 2025 in Review

32 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2025, worth a combined $111M — up 353% from $24.6M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of KLRS and 2 opened new positions — a net loss of 20 holders — while 13 trimmed existing stakes and 12 added.

The largest buyer was Samsara BioCapital, adding an estimated $112M. The largest seller was Millennium Management, cutting an estimated $1.13M.

  • 32 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2025, down from 52 in Q4 2024.
  • Funds reported $111M of Kalaris Therapeutics stock for Q1 2025, up 353% quarter-over-quarter.
  • 2 funds opened new Kalaris Therapeutics positions in Q1 2025 and 22 closed out, a net change of -20 holders.
  • The largest Kalaris Therapeutics buyer in Q1 2025 was Samsara BioCapital, an estimated $112M added.
  • The largest Kalaris Therapeutics seller in Q1 2025 was Millennium Management, an estimated $1.13M sold.

Based on aggregated 13F filings for Q1 2025.